BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board Of Directors

President of Johns Hopkins University joins BridgeBio to expand and deepen partnerships with academia PALO ALTO, Calif. – February 24, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Ronald J. Daniels, president of Johns Hopkins University, to its board of directors, effective immediately. “We […]

BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

PALO ALTO, Calif., February 21, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq: EIDX) announced today that they are presenting at two upcoming investor conferences: The SVB Leerink Annual Global Healthcare Conference on Tuesday, February 25, 2020 at 1PM (EST) in New York. The Cowen and Company Annual Health […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, CA, February 5, 2020 — BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 3, 2020, the compensation committee of BridgeBio’s board of directors granted nine new employees options to purchase an aggregate of 96,361 shares of the Company’s common stock with a per […]